Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Background: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patient...

Full description

Bibliographic Details
Main Authors: Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2021-05-01
Series:Drugs in Context
Subjects:
plaque psoriasis
psoriasis area and severity index
real life
tildrakizumab
Online Access:https://www.drugsincontext.com/treatment-of-moderate-to-severe-plaque-psoriasis-with-tildrakizumab-in-the-real-life-setting

Internet

https://www.drugsincontext.com/treatment-of-moderate-to-severe-plaque-psoriasis-with-tildrakizumab-in-the-real-life-setting

Similar Items